Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing: 1–36
Headlines: 262
Sources here: 3
Companies here: 12

Current section Germany Drug Manufacturers - General news Latest headline 13:09, 14 August 2026

Latest13:09 · 14 August 2026

finance.yahoo.com Earnings

Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Amgen stock has delivered strong gains over the past five years, yet the current share price sits at a discount to an intrinsic value estimate based on a …

Provider-linked mention 🇩🇪 Germany

Read at finance.yahoo.com

Sharemaestro market context Trend signal active 52 weeks +44.5%

Just inNext headlines

12:43 14 Aug 2026

AD HOC NEWS Market update Main company 🇩🇪 Germany

Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu

BRM main company

Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 57.3%

12:35 14 Aug 2026

nasdaq.com Market update Provider-linked mention 🇩🇪 Germany

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Key Points Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.37% fee for iShares U.S. Pharmaceuticals ETF. iShares' fund provides concentrated exposure to 56 pharmaceutical stocks, while Fidelity's holds 338 stocks across the broader healthcare sector. …

BRM mentioned

Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 57.3%

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

12:12 14 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇩🇪 Germany

Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is …

AMG mentioned

Sharemaestro market context Trend signal active 52 weeks +44.5%

12:11 14 Aug 2026

nasdaq.com Capital return Provider-linked mention 🇩🇪 Germany

SCHD vs. HDV: Which Dividend ETF Is the Better Buy for Investors?

Key Points The Schwab U.S. Dividend Equity ETF (SCHD) offers a slightly lower expense ratio and stronger recent returns than the iShares Core High Dividend ETF (HDV). HDV maintains a modestly more concentrated portfolio, with 75 holdings compared to SCHD's 103. Over the past …

AMG mentioned

Sharemaestro market context Trend signal active 52 weeks +44.5%

07:15 14 Aug 2026

finance.yahoo.com Capital return Provider-linked mention 🇩🇪 Germany

Bekaert: Update on the Share Buyback Program and the Liquidity Agreement

Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum …

BAYN mentioned

Sharemaestro market context Trend signal active 52 weeks +84.7%

07:00 14 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

AFARAK GROUP: INTERIM REPORT H1 2026

Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR …

BAYN mentioned

Sharemaestro market context Trend signal active 52 weeks +84.7%

06:00 14 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +13.2%

03:20 14 Aug 2026

nasdaq.com Deals and strategy Main company 🇩🇪 Germany

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …

BRM main company

Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 57.3%

00:09 14 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

MLP SE (WBO:MLP) (Q2 2026) Earnings Call Highlights: Record Revenue and EBIT Fuel Optimistic Outlook

This article first appeared on GuruFocus. Total Revenue: Increased by 10% to a record EUR583 million in the first half of 2026. EBIT: Reached a new record high of EUR64 million in the first half of 2026. Revenue by Competence Field: Property & Casualty …

BAYN mentioned

Sharemaestro market context Trend signal active 52 weeks +84.7%

00:07 14 Aug 2026

finance.yahoo.com Market update Main company 🇩🇪 Germany

Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +52.1%

23:01 13 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed …

GS71 main company

Sharemaestro market context Price below Trend Line 52 weeks +41.1% · Next-week setup positive 57.6%

22:46 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …

GIS mentioned

Sharemaestro market context Price below Trend Line 52 weeks +18.2% · Next-week setup positive 57.6%

22:12 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Product Image (Photo: Bristol Myers Squibb)ZENBEXUS™ (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment …

BRM mentioned

Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 57.3%

21:44 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," …

BRM mentioned

Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 57.3%

21:00 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

Assembly Biosciences, Inc. – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) …

GIS mentioned

Sharemaestro market context Price below Trend Line 52 weeks +18.2% · Next-week setup positive 57.6%

19:59 13 Aug 2026

finance.yahoo.com Macro sensitivity Provider-linked mention 🇩🇪 Germany

Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success

Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality. Exton, PA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The hemophilia gene therapy market is …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.2%

19:38 13 Aug 2026

finance.yahoo.com Market update Main company 🇩🇪 Germany

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly …

NOV main company LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +23.9% · Next-week setup positive 59.0%

18:48 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

18:48 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

18:32 13 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇩🇪 Germany

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

18:20 13 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …

NOV main company LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +23.9% · Next-week setup positive 59.0%

18:11 13 Aug 2026

finance.yahoo.com Balance sheet Provider-linked mention 🇩🇪 Germany

Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the …

GIS mentioned

Sharemaestro market context Price below Trend Line 52 weeks +18.2% · Next-week setup positive 57.6%

17:34 13 Aug 2026

finance.yahoo.com Market update Main company 🇩🇪 Germany

Sanofi: Information concerning the total number of voting rights and shares - July 2026

Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the …

SNW main company

Sharemaestro market context Price below Trend Line 52 weeks -6.3%

16:54 13 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇩🇪 Germany

European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2

The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

16:33 13 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇩🇪 Germany

Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent

(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade …

NOT mentioned

Sharemaestro market context Trend signal active 52 weeks +32.0% · Next-week setup positive 64.7%

16:12 13 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +13.2%

16:12 13 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the …

NOV main company LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +23.9% · Next-week setup positive 59.0%

16:02 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.2%

15:49 13 Aug 2026

nasdaq.com Market update Provider-linked mention 🇩🇪 Germany

Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow -- that's a 0.4% decrease week over week (from …

GIS mentioned

Sharemaestro market context Price below Trend Line 52 weeks +18.2% · Next-week setup positive 57.6%

15:30 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications

WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 / Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

15:26 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

15:05 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore

2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

15:00 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 …

RHO mentioned BRM mentioned

Sharemaestro market context Price above Trend Line 52 weeks +44.8% · Next-week setup positive 61.8%

14:42 13 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

14:15 13 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇩🇪 Germany

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%